Newport-based technology consultancy de Novo Solutions is the fastest-growing private company in Wales in the annual Sunday ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.

As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...

The S&P 500 climbed roughly 3% to a record close and its first all-time high since February. The Nasdaq Composite rose about 4%, also hitting a fresh record, as investors continued to pile into ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical giant has far too much going its way. Analysts predict that the weight ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...